entertainment -WSS

entertainment

author：leisure time 2025-08-28 08:39:40 - browse：75

A phone screen displays the webpage of Medicare.gov — coverage from STAT — Adobe

Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： FDA approves first new drug developed for postpartum depression

focus

hotspot

explore

WSS

Xenotransplantation trials will require adjusting expectations, experts say

Altering the blood type of lungs raises potential for universal organs for transplants

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Medicare drug price negotiation continues, as pharma counteroffers

Eli Lilly’s Mounjaro succeeds in second weight

Patients, doctors are clashing about side effects of hormonal birth control

focus

entertainment

leisure time

Medicare proposal to cover medical devices draws a mixed reaction

Eli Lilly’s Mounjaro succeeds in second weight

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Streamlined flu vaccines recommended by FDA advisory panel

Alkermes shareholders re

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

BioMarin wins approval for gene therapy to treat hemophilia A

Living organ donors deserve priority status for transplants

After affirmative action ruling, medical educators look to 'holistic review'

Eli Lilly’s Mounjaro succeeds in second weight

entertainment

Bispecific antibodies are next new thing in cancer immunotherapy

Eli Lilly’s Mounjaro succeeds in second weight

Lack of health data on LGBTQ+ people has serious consequences

Senate panel passes drug pricing bills, but drops one PBM reform

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Why Talkspace is targeting Medicare, a tricky market

focus

hotspot

explore

explore